What we're reading, January 29, 2016: newly approved hepatitis C cure will increase competition; California will vote on a proposition to control the cost of prescription drugs; and a special report details drug shortages and rationing decisions.
There is now more competition in the hepatitis C drug market. Merck’s once-daily pill was approved yesterday, and it will sell for much less than Gilead Science’s treatment. Reuters reported that Zepatier will be $54,600 for a 12-week regimen compared with more than $90,000 for the same 12-week regimen of Harvoni, Gilead’s once-daily pill. Merck’s Zepatier cured hepatitis C in more than 94% of patients. FDA approved the treatment with or without ribavirin for patients infected with genotype 1 and genotype 4.
The expensive hepatitis C drugs brought national attention to the cost of drugs when Gilead’s Sovaldi hit the market, and scrutiny has only intensified in the years since. Now California voters will be able to weigh in on a proposition to help control the cost of prescription drugs. Under the proposition, the state would not be able to pay more for medications than the Department of Veterans Affairs, which would mean driving a harder bargain and lowering the cost of medication for any program where the state pays for a drug, reported Kaiser Health News.
A special report from The New York Times detailed the impact of when there is a national drug shortage. According to the article, shortages have led to medical institutions making the hard decision about who gets a drug, which has led “murky ethical reasoning and medically questionable practices.” In addition, physicians and hospitals often do not tell patients about shortages and drug rationing.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More